Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | F7 | P08709 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186165 | 0.86 | MAOB (0.71) | MAOBMAOAFFAR1SCN9A | |
| SCHEMBL7395373 | 0.84 | F2 (0.58) | MAOBMAOAF2F7FFAR1 | |
| SCHEMBL964395 | 0.83 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL8935324 | 0.83 | F2 (0.64) | MAOBMAOAF2F7FFAR1 | |
| SCHEMBL31060850 | 0.83 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL2185997 | 0.83 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL2018555 | 0.83 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL9627186 | 0.82 | ACACB (0.64) | MAOBMAOAF2F7FFAR1 | |
| SCHEMBL8935327 | 0.81 | MAOB (0.58) | MAOBMAOAFFAR1RXRARXRB | |
| SCHEMBL8935367 | 0.81 | F2 (0.61) | MAOBMAOAF2F7FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| EP-1658062-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARM SPA (IT) | 2010-02-17 | — | — | EP | claimed |
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| EP-1658062-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| WO-2005102300-A1 | α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-11-03 | — | — | WO | claimed |
| EP-1588704-A1 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-26 | — | — | EP | claimed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | claimed |
| US-6306903-B1 | ANALGESICS FOR ALLEVIATION OF CHRONIC AND NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-23 | — | — | US | claimed |
| EP-1045830-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-25 | — | — | EP | claimed |
| WO-1999035125-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | PSEN1, MAPT, AADAT | MAOB 709/4885MAOA 506/4885F2 1275/4885 |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | IL1A, AADAT, DNPEP | MAOB 1206/4885MAOA 525/4885F2 1008/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | MAOB 53/4885MAOA 58/4885F2 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.